Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
|Recommended Dilution (Conc)
||Citrate Buffer pH 6.0
||30 min at Room Temperature
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Anti-Cytokeratin 7 Antibody Clone: OV-TL 12/30
Host and Isotype: Mouse IgG1, kappa
Recommended Positive Control Sample: Skin, Lung
Cellular Localization of Antibody OV-TL 12/30 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Lot specific. Plese contact tech support
Immunogen: BALB/C mice were immunized with ovarian carcinoma cell line, OTN11.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
Cytokeratin 7 Information for Pathologists
Type II keratin of simple nonkeratinizing epithelia; molecular weight 51.4 kDa (OMIM: 148059 [Accessed 14 September 2018]). Expression similar to but more limited than keratins 8 and 18 in simple, pseudostratified and ductal epithelium, mesothelium and urothelium. Essential features Membranous / cytoplasmic marker with expression in many normal epithelia and epithelial tumors. Despite wide distribution, useful as part of a panel in determining primary site of metastatic carcinoma.
Common Uses By Pathologists:
CK7 / CK20 profiles (general patterns, specificity varies):. CK7+ / CK20+: Extrahepatic carcinoma of the bile duct (majority) (Pathol Res Pract 2003;199:65). Gastric adenocarcinoma, subset (majority are CK7+ / CK20-) . Pancreatic adenocarcinoma, minor subset (co-expression associated with worse prognosis, however, majority are CK7+ / CK20-) (Cancer 2006;106:693).
Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.